ACTU ACTUATE THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1652935 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY23.4%
TTM EPS YoY-323.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-364.7%
ROA-176.4%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets125.1%
Debt / equity—
Current ratio0.73x
Interest coverage-925.44x
Cash quality & payout
Operating cash flow / net income0.87x
Accruals ratio-22.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $1.81M | $2.07M | $2.57M | $2.13M | $2.18M | $2.76M | $3.22M | $3.69M |
| SG&A expense | $1.63M | $2.84M | $3.14M | $2.56M | $3.29M | $3.20M | $3.15M | $2.87M |
| Operating income | -$3.44M | -$4.91M | -$5.71M | -$4.69M | -$5.47M | -$5.97M | -$6.37M | -$6.56M |
| Interest expense | $5,063 | $5,063 | $5,062 | $5,062 | $5,063 | $5,062 | $5,063 | $5,076 |
| Net income | -$3.42M | -$4.87M | -$5.63M | -$4.55M | -$5.41M | -$5.95M | -$6.32M | -$6.45M |
| EPS (basic) | -0.14 | -0.20 | -0.24 | — | -0.25 | -0.30 | -0.32 | — |
| EPS (diluted) | -0.14 | -0.20 | -0.24 | — | -0.25 | -0.30 | -0.32 | — |
| Weighted avg. shares (diluted) | 24.22M | 23.87M | 23.54M | — | 21.39M | 19.65M | 19.50M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $2.10M | $4.43M | $8.13M | $13.16M | $16.92M | $6.49M | $3.89M | $8.64M |
| Current assets | $2.65M | $4.75M | $8.52M | $13.64M | $17.44M | $6.69M | $4.25M | $9.21M |
| Total assets | $3.22M | $5.20M | $8.91M | $14.04M | $17.71M | $6.97M | $4.48M | $9.32M |
| Current liabilities | $3.62M | $3.81M | $4.72M | $5.71M | $6.37M | $9.20M | $9.15M | $8.80M |
| Total liabilities | $4.03M | $4.21M | $5.13M | $6.11M | $6.78M | $9.62M | $9.57M | $9.21M |
| Shareholders' equity | -$808,966 | $989,152 | $3.78M | $7.92M | $10.94M | -$2.65M | -$5.09M | $104,186 |
| Shares outstanding | 24.75M | 24.01M | 23.71M | 23.25M | 23.24M | 20.47M | 19.53M | 19.53M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.95M | -$4.41M | -$5.02M | -$3.74M | -$6.68M | -$4.17M | -$4.62M | -$4.77M |
| Financing cash flow | $626,781 | $696,960 | -$8,092 | -$29,297 | $17.11M | $6.78M | -$133,477 | -$109,412 |
| Stock-based compensation | $970,824 | $1.34M | $1.36M | $1.54M | $1.80M | $1.58M | $1.13M | $1.19M |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.